BioLineRx (BLRX) Net Margin (2023 - 2025)
Historic Net Margin for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to 445.67%.
- BioLineRx's Net Margin fell 3695600.0% to 445.67% in Q3 2025 from the same period last year, while for Sep 2025 it was 108.68%, marking a year-over-year increase of 499300.0%. This contributed to the annual value of 66.63% for FY2024, which is 9925800.0% up from last year.
- BioLineRx's Net Margin amounted to 445.67% in Q3 2025, which was down 3695600.0% from 666.78% recorded in Q2 2025.
- In the past 5 years, BioLineRx's Net Margin ranged from a high of 1505.71% in Q1 2023 and a low of 1716.63% during Q4 2023
- In the last 3 years, BioLineRx's Net Margin had a median value of 260.89% in 2025 and averaged 374.15%.
- Over the last 5 years, BioLineRx's Net Margin had its largest YoY gain of 16490600bps in 2024, and its largest YoY loss of -15625000bps in 2024.
- BioLineRx's Net Margin (Quarter) stood at 1716.63% in 2023, then surged by 96bps to 67.57% in 2024, then tumbled by -560bps to 445.67% in 2025.
- Its last three reported values are 445.67% in Q3 2025, 666.78% for Q2 2025, and 772.94% during Q1 2025.